| Guidelines on nicotine dose selection for in vivo research SG Matta, DJ Balfour, NL Benowitz, RT Boyd, JJ Buccafusco, ... Psychopharmacology 190, 269-319, 2007 | 932 | 2007 |
| Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ... Nature genetics 49 (7), 1126-1132, 2017 | 632 | 2017 |
| Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver: cDNA and deduced amino acid sequence and distinct … T Aoyama, S Yamano, DJ Waxman, DP Lapenson, UA Meyer, V Fischer, ... Journal of Biological Chemistry 264 (18), 10388-10395, 1989 | 588 | 1989 |
| A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes ES Messina, RF Tyndale, EM Sellers The Journal of pharmacology and experimental therapeutics 282 (3), 1608-1614, 1997 | 579 | 1997 |
| Nicotine metabolism defect reduces smoking ML Pianezza, EM Sellers, RF Tyndale Nature 393 (6687), 750-750, 1998 | 578 | 1998 |
| Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity D Dempsey, P Tutka, P Jacob III, F Allen, K Schoedel, RF Tyndale, ... Clinical Pharmacology & Therapeutics 76 (1), 64-72, 2004 | 494 | 2004 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process K E Caudle, T E Klein, J M Hoffman, D J Muller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209-217, 2014 | 471 | 2014 |
| Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence V Malaiyandi, EM Sellers, RF Tyndale Clinical Pharmacology & Therapeutics 77 (3), 145-158, 2005 | 369 | 2005 |
| Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians KA Schoedel, EB Hoffmann, Y Rao, EM Sellers, RF Tyndale Pharmacogenetics and Genomics 14 (9), 615-626, 2004 | 368 | 2004 |
| Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation C Lerman, R Tyndale, F Patterson, EP Wileyto, PG Shields, A Pinto, ... Clinical Pharmacology & Therapeutics 79 (6), 600-608, 2006 | 345 | 2006 |
| Nicotine-dependence symptoms are associated with smoking frequency in adolescents J O'Loughlin, J DiFranza, RF Tyndale, G Meshefedjian, E McMillan-Davey, ... American journal of preventive medicine 25 (3), 219-225, 2003 | 344 | 2003 |
| Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking Y Rao, EWA Hoffmann, M Zia, L Bodin, M Zeman, EM Sellers, RF Tyndale Molecular pharmacology 58 (4), 747-755, 2000 | 339 | 2000 |
| The pharmacogenetics research network: from SNP discovery to clinical drug response KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ... Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007 | 314 | 2007 |
| Inhibition of cytochromes P450 by antifungal imidazole derivatives W Zhang, Y Ramamoorthy, T Kilicarslan, H Nolte, RF Tyndale, EM Sellers Drug Metabolism and Disposition 30 (3), 314-318, 2002 | 301 | 2002 |
| Nicotine without smoke: Tobacco harm reduction A Amos, D Arnott, P Aveyard, L Bauld, I Bogdanovica, J Britton, ... Royal College of Physicians, 2016 | 298 | 2016 |
| Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo … C Lerman, RA Schnoll, LW Hawk, P Cinciripini, TP George, EP Wileyto, ... The lancet Respiratory medicine 3 (2), 131-138, 2015 | 292 | 2015 |
| Cytochrome P450 enzymes in the brain: emerging evidence of biological significance CS Ferguson, RF Tyndale Trends in pharmacological sciences 32 (12), 708-714, 2011 | 292 | 2011 |
| Genetics of alcohol and tobacco use in humans RF Tyndale Annals of medicine 35 (2), 94-121, 2003 | 292 | 2003 |
| CYP2A6 genotype and the metabolism and disposition kinetics of nicotine NL Benowitz, GE Swan, P Jacob III, CN Lessov‐Schlaggar, RF Tyndale Clinical Pharmacology & Therapeutics 80 (5), 457-467, 2006 | 271 | 2006 |
| Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain S Miksys, C Lerman, PG Shields, DC Mash, RF Tyndale Neuropharmacology 45 (1), 122-132, 2003 | 265 | 2003 |